FMP
Spectrum Pharmaceuticals, Inc.
SPPI
NASDAQ
Inactive Equity
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.
1.02 USD
-0.005 (-0.488%)
Proactive Investors
Aug 19, 2024
NanoViricides (NYSE-A:NNVC) is advancing its clinical program with plans for an innovative Phase II trial of its drug candidate NV-387, the company announced Monday. The drug candidate NV-387, which has shown promise in treating various viral infections including RSV, COVID-19, and Influenza in animal studies, could revolutionize the treatment of respiratory viruses, according to the company.
Proactive Investors
Nov 28, 2023
NanoViricides (NYSE-A:NNVC) has successfully wrapped up the first phase of a human clinical trial for its broad-spectrum antiviral drug, NV-CoV-2. The company said that the drug was well-tolerated, with no adverse events reported in any of the three dose levels from the two formulations used in the study, namely NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies.
Proactive Investors
Aug 21, 2023
NanoViricides (NYSE-A:NNVC) has reported that the Phase 1a/1b human clinical trial of its broad-spectrum antiviral drug NV-CoV-2 is progressing successfully. According to the company's Indian collaborator and drug sponsor, Karveer Meditech, about 26 out of the target of 36 healthy volunteers in the various cohorts in the Phase 1a Single-Ascending-Dose (SAD) have already completed the study.
Seeking Alpha
Jun 22, 2023
Spectrum and Assertio's merger would lead to a diversified product portfolio and a combination of two unique marketing strategies. Spectrum's ROLVEDON has the potential to become the standard of care for reducing chemotherapy-induced neutropenia in a $3B domestic market. The combined companies of Assertio and Spectrum are estimated to provide a return of 4x.
Zacks Investment Research
May 9, 2023
Spectrum Pharmaceuticals (SPPI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.09 per share a year ago.
PennyStocks
May 8, 2023
Penny stocks to buy for under $1 but are they worth the risk? The post 7 Hot Penny Stocks Under $1.10 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
PennyStocks
May 5, 2023
Penny stocks to watch this week. The post Best Penny Stocks To Buy?
Proactive Investors
Apr 25, 2023
Spectrum Pharmaceuticals (NASDAQ:SPPI) stock is soaring after an all-stock acquisition deal with Assertio Holdings was announced Tuesday morning. The $248 million purchase price values Spectrum shares at $1.14 each, a significant premium over its Tuesday closing price of $0.69.
InvestorPlace
Apr 25, 2023
Spectrum Pharmaceuticals (NASDAQ: SPPI ) stock is soaring higher on Tuesday thanks to an acquisition deal with Assertio (NASDAQ: ASRT ). This deal will have Assertio acquire all outstanding shares of SPPI stock.
24/7 Wall Street
Apr 3, 2023
The healthcare sector has more high return generating companies than many other sectors.